Humacyte Q3 2026 Earnings Date & Estimates

Humacyte (NASDAQ:HUMA) is a biotechnology company developing and manufacturing bioengineered human tissues for use in regenerative medicine. Its technology platform is designed to produce off-the-shelf, implantable tissues that can be stored and transported for use when needed, potentially reducing reliance on tissue obtained directly from patients or human donors.

The company’s primary product is SYMVESS, an acellular tissue-engineered vascular graft designed to replace or repair damaged blood vessels. In December 2024, the U.S. Food and Drug Administration approved SYMVESS for use in adults with extremity arterial injuries requiring vascular replacement when an appropriate vein is unavailable. Humacyte has also investigated its vascular graft technology for applications including arteriovenous access for hemodialysis, vascular trauma, peripheral arterial disease, and pediatric heart surgery.

Humacyte was founded in 2004 by Dr. Laura Niklason, a physician-scientist and biomedical engineer, who serves as the company’s chief executive officer. The company is headquartered in Durham, North Carolina, and has conducted development and clinical activities primarily in the United States, with additional research involving international sites and collaborators.